Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes

Terpstra, Wim; Leenen, Pieter J. M.; Bos, Cor van den; Prins, A; Loenen, W. A. M.; Verstegen, Monique M A; Wyngaardt, Sandra Van; Rooijen, Nico van; Wognum, Albertus W.; Wagemaker, Gerard; Wielenga, Jenne J.; Löwenberg, Bob

doi:10.1038/sj.leu.2400694

Cited by 39 publications

(38 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,16,19,24,25 To our knowledge, there has been no previous comparison of NOD/SCID, SCID and Nude mice in their ability to permit growth of Raji, Daudi or Namalwa lymphoma cells. Previous studies of human leukemias comparing Nude and SCID mice demonstrated the superiority of SCID mice in supporting the growth of BALL-1, Molt-4, CEM and A-1 human leukemia cell lines.…”

Section: Discussionmentioning

confidence: 99%

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects

Hudson

et al. 1998

Leukemia

View full text Add to dashboard Cite

While it is known that mice with genetic immune defects are useful for establishing durable engraftment of human tumor xenografts, the relative role of components of host innate and adoptive immunity in engraftment has not been determined. We directly compared the ability of four strains of genetically immunodeficient mice (NOD/SCID, SCID, Nude and Rag-1-deficient) to successfully engraft and support the human cell lines Daudi, Raji, Namalwa and Molt-4 as subcutaneous tumors. We additionally examined the effect of further immunosuppression of the mice by whole body irradiation at a dose of 600 cGy for Nude and Rag-1 and 300 cGy for SCID mice and by administration of anti-natural killer (asialo-GM1) antibody on tumor growth. Mice with each of the defects supported xenografts to varying degrees. We found differences in growth characteristics in the cell lines tested, with Namalwa consistently producing the largest tumors. With all cell lines studied, optimal growth was achieved using NOD/SCID mice. Overall, tumor growth was somewhat enhanced by pretreatment with radiation with little additional benefit from the addition of anti-asialo-GM1 antibody. The importance of multiple components of the innate and adoptive immune system in xenotransplantation were best demonstrated when results in untreated NOD/SCID mice were compared to SCID, nude and RAG-1-deficient mice. The NOD/SCID mouse with or without additional immunosuppression provides the optimal model for the study of the biology and treatment of human leukemias and lymphomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects

Hudson

et al. 1998

Leukemia

View full text Add to dashboard Cite

show abstract

“…The disadvantages of NOD/ SCID mice included the frequent occurrence of thymic lymphoma and discernable NK cell activity , which hindered execution of enduring engraftment. While various strategies had been evaluated co-transplantation of growth, only 70% of all AML samples exhibited detectible engraftment in NOD/SCID mice (Terpstra et al, 1997;Ailles et al, 1999;Bonnet et al, 1999;Rombouts et al, 2000b;Nitsche et al, 2003). The shortened life span of this strain (mean 8.5 months) also limited the duration of tumor watches (Ishikawa et al, 2007).…”

Section: Doimentioning

confidence: 99%

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Shan

Ma²

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The discovery of the immunodeficient mice has provided a tool for establishing animal models as hosts for in vivo analysis of AML. Various model systems have been established in the last few decades, and it is essential that murine AML models are developed to exploit more specific, targeted therapeutics. In this review, we concentrate on the models of AML and discuss the development of immunodeficiency models for understanding of leukemogenesis, describe those now available and their values and document the methods used for establishing and identifying AML mice models, as well as factors influencing engraftment of human AML in immunodeficient mice. Thus, the function of this article is to provide clinicians and experimentalists with a chronological, comprehensive appraisal of all AML model systems. Keywords: SCID -NOD/SCID -acute myeloid leukemia (AML) -model MINI-REVIEW How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient MiceWu-Lin Shan 1,2 , Xiao-Ling Ma 1,2 * patients. Despite intensive effort from many laboratories around the world, none of the existing models was ideal. Considerable progress has been made by using a variety of complementary approaches. This review will emphasize the advantages and drawbacks of the human AML models established by using immunodeficient mice.

show abstract

“…4,276,[374][375][376][377][378][379][380][381][382][383] Despite the obvious advantages of the NOD/SCID model over all other immunodeficient models, there are still some inherent obstacles. While various strategies, including hu-cytokine supplementation, 364,370,[384][385][386] co-transplantation of growth factor-producing cell lines or 'accessory cells' 384,385 have been evaluated, only 70% of all AML samples exhibit detectible engraftment in NOD/SCIDs. 364 Additionally, the development of thymic lymphomas by 8.5 months, 387 extreme radiosensitivity 387 and discernable NK cell activity 387 hinder execution of enduring engraftment.…”

Section: Nude Modelsmentioning

confidence: 99%

Animal models of acute myelogenous leukaemia – development, application and future perspectives

2005

View full text Add to dashboard Cite

From the early inception of the transplant models through to contemporary genetic and xenograft models, evolution of murine leukaemic model systems have been critical to our general comprehension and treatment of cancer, and, more specifically, disease states such as acute myelogenous leukaemia (AML). However, even with modern advances in therapeutics and molecular diagnostics, the majority of AML patients die from their disease. Thus, in the absence of definitive in vitro models which precisely recapitulate the in vivo setting of human AMLs and failure of significant numbers of new drugs late in clinical trials, it is essential that murine AML models are developed to exploit more specific, targeted therapeutics. While various model systems are described and discussed in the literature from initial transplant models such as BNML and spontaneous murine leukaemia virus models, to the more definitive genetic and clinically significant NOD/SCID xenograft models, there exists no single compendium which directly assesses, reviews or compares the relevance of these models. Thus, the function of this article is to provide clinicians and experimentalists a chronological, comprehensive appraisal of all AML model systems, critical discussion on the elucidation of their roles in our understanding of AML and consideration to their efficacy in the development of AML chemotherapeutics.

show abstract

Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes

Cited by 39 publications

References 4 publications

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects

How to Establish Acute Myeloid Leukemia Xenograft Models Using Immunodeficient Mice

Animal models of acute myelogenous leukaemia – development, application and future perspectives

Contact Info

Product

Resources

About